On Jan. 08, Szekeres David Leslie divested U.S. $70,219 in shares of Heron Therapeutics Inc.. The EVP, COO sold 3,571 shares at a price per share of $19.66. The transaction decreased this specific insider’s holdings to 0 shares worth around $0.0 at present.
Guggenheim launched its Heron Therapeutics Inc. [HRTX] rating to the equivalent of a Buy and assigned the price target of $24, in a research note dated May 27, 2020. That figure represents around a 18.25% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with Guggenheim’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in late May. Meanwhile, Needham had maintained its rating on HRTX to the earlier “Buy” rating, in a research note produced for clients February 20, 2020. In addition, there was no change from Needham on January 16, 2019. The rater maintained HRTX to “a Buy” but assigned new target price of $64.
Is Heron Therapeutics Inc. [NASDAQ:HRTX] a Good Buy Right Now?
It should be noted that HRTX technical indicators for short, intermediate as well as long term progress have placed an overall average of 80% as Buy. The average signal changed from 100% Buy in the last week and compares with 100% Buy in the past month. Data from Heron Therapeutics Inc.’s Trend Spotter indicated that the signals were Bullish. The stock current average is 1.22 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 1.03 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.88 million shares.
HRTX Price Performance
On Wall Street, Heron Therapeutics Inc. [NASDAQ:HRTX] finished Friday’s session up 0.51% at $19.62. The stock went up to $20.12 at the same session while its lowest single day price was $19.42. In the last five days, it saw a fall of about -7.30%, Heron Therapeutics Inc. shares dropped by almost -7.30% since the beginning of the year. However, the share price has dropped to as low as -20.76% below its one year high. On 01/04/21, the company shares recorded $21.64, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/07/21, the same year at $19.21. The company’s shares have declined by -8.06% in the past year. The 50-day SMA achieved is $18.34 while the 200-day SMA is $16.46. Volume dropped to 0.64 million from 0.79 million in the previous session.
HRTX Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 19.32 level, and in case of violation of this particular level, it will cause more drop to 19.02 level. On the upper level, 20.42 is still the key resistance. The stock may increase to the subsequent resistance at 20.02. The Relative Strength Index (RSI) pinned on the 14-day chart is 51.85, implying a neutral technical stance while the MACD stands at -0.81, meaning price will decrease in the next trading period. Percent R indicator moved to 66.05%, implying low price movement. Stochastic %K at 35.82% suggest holding the stock.
What is the short interest in Heron Therapeutics Inc.?
Short interest in the Heron Therapeutics Inc. stock has surged, increasing by 0.5 million shares to total 17.6 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 18.1 million, data from Yahoo Finance shows. The decrease of -2.84% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 23.58% of the overall float for the stock.
Heron Therapeutics Inc.’s Biggest Shareholders: Who Owns Heron Therapeutics Inc. [HRTX]?
Filings by Franklin Advisers, Inc. showed that the firm now holds a total of 12,833,938 shares or roughly 14.13% of the outstanding HRTX shares. This means their shares have increased by 316,556 from the 12,833,938 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, The Vanguard Group, Inc. updated stake is worth $134,213,935. Details in the latest 13F filings reveal that Baker Bros. Advisors LP disposed off their -0.39% stake valued at $103,888,220 while BlackRock Fund Advisors cut theirs at $88,840,321. During the last quarter, Baker Bros. Advisors LP liquidated -23,400 of its shares in Heron Therapeutics Inc. while BlackRock Fund Advisors sold -248,509 shares. The ArrowMark Colorado Holdings LLC’s holdings currently number 5,059,526 shares at $99267900.12. According to the firm’s last 13F report, SSgA Funds Management, Inc. shares in the company at filing stood at 4,410,234 shares, roughly $76,429,355.
HRTX Earnings Forecast For The Current Quarter
Heron Therapeutics Inc. [HRTX] is expected to report weak earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $16.86M and an earnings per share of -$0.67 for Dec 2020. Looking further ahead, the company is expected to report revenue of $23.23M at an EPS of -$0.63 for Mar 2021. The estimates represent downside of 80.40% and 29.30% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
HRTX Earnings Estimates For The Current Year
For the financial year, Heron Therapeutics Inc. [NASDAQ:HRTX] is expected to bring in revenue of $84.93M. The returns are nearly $-61.04 million lower than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -2.49, higher than that of FY19 by $0.01. Estimates put this year’s earnings growth at 0.40%, 29.30% for the next, and at an annual 47.50% over the next 5-year period. As for sales, forecasts are for a decrease of -41.80% in the current fiscal year and a further 80.40% over the following year.
What are analyst thoughts on Heron Therapeutics Inc.?
Looking forward to the Heron Therapeutics Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for Heron Therapeutics Inc. stock at $26.00 within the next 12 months, which represents almost 24.54 per cent growth from its previous closing price of $19.62. The highest analysts’ target for Heron Therapeutics Inc. stock projections is $70.00 and the lowest one is $24.00. Still, 9 analysts sharing their consensus rating for HRTX stock in 2021 agree that it is a Buy.